CLAIM CARDS
Claim Cards
Atomic claims extracted from accepted Researka artifacts, with source support, contradiction state, and provenance links when available.
Filtered to publication 9e9f3163-3f3b-4c1f-9790-a8b1400b8696
exploratory
Evidence-honesty note: 35/44 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.
Contradiction: none
Sources: 5
exploratoryThe evidence profile contains no sources classified primarily as direct interventional hard-endpoint evidence, 38 adjacent clinical sources, and 4 mechanistic or model-system sources, with 509 cross-study disagreements across the evidence base.
Contradiction: none
Sources: 5
exploratoryNo single positive outcome class dominates the retained corpus; null signals cluster in the contextual adjacent evidence, immune and inflammation, longevity outcome classes, and negative signals cluster in the contextual adjacent evidence and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.
Contradiction: none
Sources: 5
exploratoryThe conclusion is that epigenetic clocks should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.
Contradiction: none
Sources: 5
exploratoryOutcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.
Contradiction: none
Sources: 5
exploratory| Contextual Adjacent Evidence | n=32; claims=1073 | no extracted directional signal in 28/32 sources | 28 indirect; 3 mechanistic; 1 review | limited corpus depth in this outcome class |
Contradiction: none
Sources: 5
exploratoryThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.
Contradiction: none
Sources: 5
exploratory32 included sources were assigned to this outcome class. Directional coding: mixed=1, negative=1, null=28, unclear=2. Directness coding: indirect=28, mechanistic=3, review=1.
Contradiction: none
Sources: 5
exploratory5 included sources were assigned to this outcome class. Directional coding: negative=1, null=3, unclear=1. Directness coding: indirect=5.
Contradiction: none
Sources: 5
exploratory3 included sources were assigned to this outcome class. Directional coding: null=3. Directness coding: indirect=3.
Contradiction: none
Sources: 5
exploratory3 included sources were assigned to this outcome class. Directional coding: null=1, unclear=2. Directness coding: indirect=1, review=2.
Contradiction: none
Sources: 5
exploratoryVerification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.
Contradiction: none
Sources: 5
exploratoryThe curated corpus is dominated by observational cohort designs; no large, long-term randomized controlled trial testing whether modulating epigenetic clocks extends human lifespan or reduces hard clinical endpoints such as incident dementia or cardiovascular death was represented. Consequently, the headline conclusion that accelerated epigenetic aging predicts adverse outcomes cannot be interpreted as causal, and the specific question of whether therapeutic epigenetic age reversal improves survival remains unanswered by this evidence base.
Contradiction: none
Sources: 5
exploratoryThe corpus provides limited evidence for mechanism-to-clinic translation because preclinical and mechanistic findings were not corroborated by matched human intervention data. Marinello 2025 demonstrated in a preclinical ovary model that epigenetic age tracked with ovarian reserve markers, yet no human trial in the corpus tested whether pharmacological rescue of ovarian aging alters clock readings. Pending further randomized trials, the use of epigenetic clocks as primary endpoints to guide anti-aging interventions or to market a proven standalone geroprotective intervention is not currently supported.
Contradiction: none
Sources: 5
exploratoryFor epigenetic clocks, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation.The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.
Contradiction: none
Sources: 5
exploratoryThis synthesis maps 44 included sources on Epigenetic clock across 5 outcome classes and 509 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.
Contradiction: none
Sources: 5
exploratoryAcross 44 curated reference papers, the evidence base for Epigenetic clock shows a context-dependent profile. Negative signals appear in: contextual other, longevity. Null findings dominate: contextual other, immune inflammation. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Epigenetic clock anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.
Contradiction: none
Sources: 5
exploratoryThe strongest unresolved contrast is the disagreement between Bozack 2023 and Corley 2023 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over.
Contradiction: none
Sources: 5
exploratoryPrior reviews in the corpus (Fransquet 2019) emphasize convergent signals on Epigenetic clock. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.
Contradiction: none
Sources: 5
exploratory| longevity | 0 | 5 | negative, null, unclear | direct interventional hard-endpoint gap |
Contradiction: none
Sources: 5
exploratory| contextual adjacent evidence | 0 | 32 | mixed, negative, null, unclear | conflict-resolution gap |
Contradiction: none
Sources: 5
exploratory| mortality and survival | 0 | 3 | null, unclear | direct interventional hard-endpoint gap |
Contradiction: none
Sources: 5
exploratory| immune and inflammation | 0 | 3 | null | direct interventional hard-endpoint gap |
Contradiction: none
Sources: 5
exploratory| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 5 indirect sources; direction profile: negative, null, unclear |
Contradiction: none
Sources: 5
exploratory| P3 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 32 indirect sources; direction profile: mixed, negative, null, unclear |
Contradiction: none
Sources: 5
exploratory| P4 | mortality and survival: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null, unclear |
Contradiction: none
Sources: 5
exploratory| P5 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 3 indirect sources; direction profile: null |
Contradiction: none
Sources: 5
exploratoryThe next high-yield study for Epigenetic clock should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.
Contradiction: none
Sources: 5
exploratoryThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.
Contradiction: none
Sources: 5
exploratoryEvidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.
Contradiction: none
Sources: 5